Clinical Trial Update: Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating acute vasodilation response to inhaled nitric oxide in pulmonary arterial hypertension has been withdrawn by the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Geno LLC | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN